Francesco Reggiani

Mr. Francesco Reggiani

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ERErnesto Rossi
Ernesto Rossi
MCMichela Croce
Michela Croce
FRFrancesco Reggiani
Francesco Reggiani
GSGiovanni Schinzari
Giovanni Schinzari
MAMarianna Ambrosio
Marianna Ambrosio
AAAdriana Agnese Amaro
Adriana Agnese Amaro
Uveal melanoma (UM) is characterized by relatively few, highly incident molecular alterations and their association with metastatic risk is deeply understood. Nevertheless, this knowledge has so far not led to innovative therapies for the successful treatment of UM metastases or for adjuvant therapy, leaving survival after diagnosis of metastatic UM almost unaltered in decades. The driver mutations of UM, mainly in the G-protein genes GNAQ and GNA11, activate the MAP-kinase pathway as well as the YAP/TAZ pathway. At present, there are no drugs that target the latter and this likely explains the failure of mitogen activated kinase kinase inhibitors. Immune checkpoint blockers, despite the game changing effect in cutaneous melanoma (CM), show only limited effects in UM probably because of the low mutational burden of 0.5 per megabase and the unavailability of antibodies targeting the main immune checkpoint active in UM. The highly pro-tumorigenic microenvironment of UM also contributes to therapy resistance. However, T-cell redirection by a soluble T-cell receptor that is fused to an anti-CD3 single-chain variable fragment, local, liver specific therapy, new immune checkpoint blockers, and YAP/TAZ specific drugs give new hope to repeating the success of innovative therapy obtained for CM.

14 May 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
FPFrancesca Piaggio
Francesca Piaggio
MCMichela Croce
Michela Croce
FRFrancesco Reggiani
Francesco Reggiani
PMPaola Monti
Paola Monti
CBCinzia Bernardi
Cinzia Bernardi
AAAdriana Agnese Amaro
Adriana Agnese Amaro

7 January 2021 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
FDFrancesca Dassie
Francesca Dassie
RLRiccardina Lorusso
Riccardina Lorusso
SBSilvia Benavides-Varela
Silvia Benavides-Varela
GMGabriella Milan
Gabriella Milan
FFFrancesca Favaretto
Francesca Favaretto
PMPietro Maffei
Pietro Maffei

Verified
Journal Article
Open access
PDF file
SSSara Stigliani
Sara Stigliani
AAAdriana Agnese Amaro
Adriana Agnese Amaro
FRFrancesco Reggiani
Francesco Reggiani
EMElena Maccarini
Elena Maccarini
CMClaudia Massarotti
Claudia Massarotti
PSPaola Scaruffi
Paola Scaruffi
Sperm cryopreservation is a procedure widely used to store gametes for later use, to preserve fertility in patients prior to gonadotoxic treatments or surgery, and for sperm donation programs. The purpose of the study was to assess the impact of cryopreservation on human sperm transcriptome. Semen samples were collected from 13 normospermic men. Each sample was divided into two aliquots. The total RNA was immediately extracted from one aliquot. The second aliquot was frozen and total RNA was extracted after a week of storage in liquid nitrogen. The RNA samples were randomized in four pools, each of six donors, and analyzed by microarrays. The paired Significance Analysis of Microarray was performed. We found 219 lower abundant transcripts and 28 higher abundant transcripts in cryopreserved sperm than fresh sperm. The gene ontology analysis disclosed that cryopreservation alters transcripts of pathways important for fertility (i.e., spermatogenesis, sperm motility, mitochondria function, fertilization, calcium homeostasis, cell differentiation, and early embryo development), although the increase of some transcripts involved in immune response can compensate for the harmful effects of freezing.

13 December 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
AAAdriana Agnese Amaro
Adriana Agnese Amaro
MPMax Pfeffer
Max Pfeffer
Ulrich PfefferUlrich Pfeffer
Ulrich Pfeffer
FRFrancesco Reggiani
Francesco Reggiani
There is a growing number of multi-domain genomic datasets for human tumors. Multi-domain data are usually interpreted after separately analyzing single-domain data and integrating the results post hoc. Data fusion techniques allow for the real integration of multi-domain data to ideally improve the tumor classification results for the prognosis and prediction of response to therapy. We have previously described the joint singular value decomposition (jSVD) technique as a means of data fusion. Here, we report on the development of these methods in open source code based on R and Python and on the application of these data fusion methods. The Cancer Genome Atlas (TCGA) Skin Cutaneous Melanoma (SKCM) dataset was used as a benchmark to evaluate the potential of the data fusion approaches to improve molecular classification of cancers in a clinically relevant manner. Our data show that the data fusion approach does not generate classification results superior to those obtained using single-domain data. Data from different domains are not entirely independent from each other, and molecular classes are characterized by features that penetrate different domains. Data fusion techniques might be better suited for response prediction, where they could contribute to the identification of predictive features in a domain-independent manner to be used as biomarkers.

Verified
Journal Article
Open access
PDF file
FRFrancesco Reggiani
Francesco Reggiani
MAMarianna Ambrosio
Marianna Ambrosio
MCMichela Croce
Michela Croce
ETEnrica Teresa Tanda
Enrica Teresa Tanda
FSFrancesco Spagnolo
Francesco Spagnolo
AAAdriana Agnese Amaro
Adriana Agnese Amaro
The metastatic risk of uveal melanoma (UM) is defined by a limited number of molecular lesions, somatic mutations (SF3B1 and BAP1), and copy number alterations (CNA): monosomy of chromosome 3 (M3), chr8q gain (8q), chr6p gain (6p), yet the sequence of events is not clear. We analyzed data from three datasets (TCGA-UVM, GSE27831, GSE51880) with information regarding M3, 8q, 6p, SF3B1, and BAP1 status. We confirm that BAP1 mutations are always associated with M3 in high-risk patients. All other features (6p, 8q, M3, SF3B1 mutation) were present independently from each other. Chr8q gain was frequently associated with chr3 disomy. Hierarchical clustering of gene expression data of samples with different binary combinations of aggressivity factors shows that patients with 8q|M3, BAP1|M3 form one cluster enriched in samples that developed metastases. Patients with 6p combined with either 8q or SF3B1 are mainly represented in the other, low-risk cluster. Several gene expression events that show a non-significant association with outcome when considering single features become significant when analyzing combinations of risk features indicating additive action. The independence of risk factors is consistent with a random risk model of UM metastasis without an obligatory sequence.